Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer

Cancer Cell

Volumn 24, Issue 2, 2013, Pages 197-212

  Hsu, Pei Yin ^a   Hsu, Hang Kai ^a   Lan, Xun ^d   Juan, Liran ^e   Yan, PearllyS ^d   Labanowska, Jadwiga ^d   Heerema, Nyla ^d   Hsiao, Tzu Hung ^b   Chiu, Yu Chiao ^c   Chen, Yidong ^a,b   Liu, Yunlong ^e   Li, Lang ^e   Li, Rong ^a   Thompson, IanM ^a   Nephew, KennethP ^f   Sharp, ZeltonD ^a   Kirma, NameerB ^a   Jin, VictorX ^d   Huang, TimH M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d OHIO STATE UNIVERSITY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Indiana University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL PROLIFERATION; CHROMATIN; CHROMOSOME 17Q; CHROMOSOME 17Q23; CHROMOSOME 20Q; CHROMOSOME 20Q13; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84881510124     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.07.007     Document Type: Article

References (54)

1. Andersen C.L., Monni O., Wagner U., Kononen J., Bärlund M., Bucher C., Haas P., Nocito A., Bissig H., Sauter G., Kallioniemi A. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence insitu hybridization to tissue microarrays. Am. J. Pathol. 2002, 161:73-79.
2. Albertson D.G. Gene amplification in cancer. Trends Genet. 2006, 22:447-455.
3. Almstrup K., Fernández M.F., Petersen J.H., Olea N., Skakkebaek N.E., Leffers H. Dual effects of phytoestrogens result in u-shaped dose-response curves. Environ. Health Perspect. 2002, 110:743-748.
4. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
5. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.M., Wu J., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405. Australian Pancreatic Cancer Genome Initiative.
6. Bilal E., Vassallo K., Toppmeyer D., Barnard N., Rye I.H., Almendro V., Russnes H., Børresen-Dale A.L., Levine A.J., Bhanot G., Ganesan S. Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS ONE 2012, 7:e38575.
7. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
8. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., Brodsky A.S., Keeton E.K., Fertuck K.C., Hall G.F., et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 2006, 38:1289-1297.
9. Cicatiello L., Mutarelli M., Grober O.M., Paris O., Ferraro L., Ravo M., Tarallo R., Luo S., Schroth G.P., Seifert M., et al. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am. J. Pathol. 2010, 176:2113-2130.
10. Collins C., Volik S., Kowbel D., Ginzinger D., Ylstra B., Cloutier T., Hawkins T., Predki P., Martin C., Wernick M., et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res. 2001, 11:1034-1042.
11. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
12. De S., Michor F. DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat. Biotechnol. 2011, 29:1103-1108.
13. De S., Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat. Struct. Mol. Biol. 2011, 18:950-955.
14. Dekker J., Rippe K., Dekker M., Kleckner N. Capturing chromosome conformation. Science 2002, 295:1306-1311.
15. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. Invitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
16. Fullwood M.J., Liu M.H., Pan Y.F., Liu J., Xu H., Mohamed Y.B., Orlov Y.L., Velkov S., Ho A., Mei P.H., et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64.
17. Ginestier C., Cervera N., Finetti P., Esteyries S., Esterni B., Adélaïde J., Xerri L., Viens P., Jacquemier J., Charafe-Jauffret E., et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin. Cancer Res. 2006, 12:4533-4544.
18. Hagège H., Klous P., Braem C., Splinter E., Dekker J., Cathala G., de Laat W., Forné T. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protoc. 2007, 2:1722-1733.
19. Hampton O.A., Den Hollander P., Miller C.A., Delgado D.A., Li J., Coarfa C., Harris R.A., Richards S., Scherer S.E., Muzny D.M., et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res. 2009, 19:167-177.
20. Han J., Goldstein L.A., Gastman B.R., Rabinovitz A., Rabinowich H. Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J.Biol. Chem. 2005, 280:16383-16392.
21. Han W., Han M.R., Kang J.J., Bae J.Y., Lee J.H., Bae Y.J., Lee J.E., Shin H.J., Hwang K.T., Hwang S.E., et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006, 6:92.
22. Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., Vidaurre T., Holmes F., Souchon E., Wang H., et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011, 305:1873-1881.
23. Heiser L.M., Sadanandam A., Kuo W.L., Benz S.C., Goldstein T.C., Ng S., Gibb W.J., Wang N.J., Ziyad S., Tong F., et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:2724-2729.
24. Hsu P.Y., Deatherage D.E., Rodriguez B.A., Liyanarachchi S., Weng Y.I., Zuo T., Liu J., Cheng A.S., Huang T.H. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res. 2009, 69:5936-5945.
25. Hsu P.Y., Hsu H.K., Singer G.A., Yan P.S., Rodriguez B.A., Liu J.C., Weng Y.I., Deatherage D.E., Chen Z., Pereira J.S., et al. Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res. 2010, 20:733-744.
26. Hu Q., Kwon Y.S., Nunez E., Cardamone M.D., Hutt K.R., Ohgi K.A., Garcia-Bassets I., Rose D.W., Glass C.K., Rosenfeld M.G., Fu X.D. Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc. Natl. Acad. Sci. USA 2008, 105:19199-19204.
27. Jiang X., Orr B.A., Kranz D.M., Shapiro D.J. Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells. Endocrinology 2006, 147:1419-1426.
28. Joseph R., Orlov Y.L., Huss M., Sun W., Kong S.L., Ukil L., Pan Y.F., Li G., Lim M., Thomsen J.S., et al. Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol. Syst. Biol. 2010, 6:456-468.
29. Kim J., Bergmann A., Lucas S., Stone R., Stubbs L. Lineage-specific imprinting and evolution of the zinc-finger gene ZIM2. Genomics 2004, 84:47-58.
30. Knuesel M.T., Meyer K.D., Donner A.J., Espinosa J.M., Taatjes D.J. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol. Cell. Biol. 2009, 29:650-661.
31. Lieberman-Aiden E., van Berkum N.L., Williams L., Imakaev M., Ragoczy T., Telling A., Amit I., Lajoie B.R., Sabo P.J., Dorschner M.O., et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009, 326:289-293.
32. Li L., Andersen M.E., Heber S., Zhang Q. Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J.Mol. Endocrinol. 2007, 38:569-585.
33. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., Rosenfeld M.G. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
34. Lupski J.R., Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet. 2005, 1:e49.
35. Mandlekar S., Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6:469-477.
36. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., Palanisamy N., Chinnaiyan A.M. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
37. Mitchell J.A., Fraser P. Transcription factories are nuclear subcompartments that remain in the absence of transcription. Genes Dev. 2008, 22:20-25.
38. Mohr J., Helfrich H., Fuge M., Eldering E., Bühler A., Winkler D., Volden M., Kater A.P., Mertens D., Te Raa D., et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011, 117:1622-1632.
39. Monni O., Barlund M., Mousses S., Kononen J., Sauter G., Heiskanen M., Paavola P., Avela K., Chen Y., Bittner M.L., Kallioniemi A. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc. Natl. Acad. Sci. USA 2001, 98:5711-5716.
40. Nikolsky Y., Sviridov E., Yao J., Dosymbekov D., Ustyansky V., Kaznacheev V., Dezso Z., Mulvey L., Macconaill L.E., Winckler W., et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008, 68:9532-9540.
41. Osborne C.S., Chakalova L., Mitchell J.A., Horton A., Wood A.L., Bolland D.J., Corcoran A.E., Fraser P. Myc dynamically and preferentially relocates to a transcription factory occupied by Igh. PLoS Biol. 2007, 5:e192.
42. Pollack J.R., Sørlie T., Perou C.M., Rees C.A., Jeffrey S.S., Lonning P.E., Tibshirani R., Botstein D., Børresen-Dale A.L., Brown P.O. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. USA 2002, 99:12963-12968.
43. Santarius T., Shipley J., Brewer D., Stratton M.R., Cooper C.S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 2010, 10:59-64.
44. Schwab M. Oncogene amplification in solid tumors. Semin. Cancer Biol. 1999, 9:319-325.
45. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305:245-248.
46. Sinclair C.S., Rowley M., Naderi A., Couch F.J. The 17q23 amplicon and breast cancer. Breast Cancer Res. Treat. 2003, 78:313-322.
47. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
48. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., Pleasance E.D., Lau K.W., Beare D., Stebbings L.A., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
49. Symmans W.F., Hatzis C., Sotiriou C., Andre F., Peintinger F., Regitnig P., Daxenbichler G., Desmedt C., Domont J., Marth C., et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J.Clin. Oncol. 2010, 28:4111-4119.
50. Vandenberg L.N., Wadia P.R., Schaeberle C.M., Rubin B.S., Sonnenschein C., Soto A.M. The mammary gland response to estradiol: monotonic at the cellular level, non-monotonic at the tissue-level of organization?. J. Steroid Biochem. Mol. Biol. 2006, 101:263-274.
51. Visel A., Rubin E.M., Pennacchio L.A. Genomic views of distant-acting enhancers. Nature 2009, 461:199-205.
52. Wang L.H., Yang X.Y., Zhang X., An P., Kim H.J., Huang J., Clarke R., Osborne C.K., Inman J.K., Appella E., Farrar W.L. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006, 10:487-499.
53. Welboren W.J., van Driel M.A., Janssen-Megens E.M., van Heeringen S.J., Sweep F.C., Span P.N., Stunnenberg H.G. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J. 2009, 28:1418-1428.
54. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.